Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 3/20 | 0.63 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.56 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.56 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | CASR | P41180 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19227013 | 0.85 | ABCB1 (0.64) | CYP2D6LMNAMAPTHTTSMN1; SMN2 | |
| SCHEMBL22359960 | 0.84 | CYP2D6 (0.58) | CYP2D6LMNAADRB2ADRB1ADRB3 | |
| SCHEMBL16093325 | 0.84 | USP2 (0.57) | CYP2D6LMNAKDM4EMAPTTSHR | |
| SCHEMBL23895833 | 0.82 | BACE1 (0.46) | CYP2D6LMNAADRB2ADRB1ADRB3 | |
| SCHEMBL22710404 | 0.82 | MAPT (0.57) | CYP2D6LMNAKDM4EMAPTTSHR | |
| SCHEMBL267463 | 0.82 | LMNA (0.68) | CYP2D6LMNAADRB2ADRB1ADRB3 | |
| SCHEMBL22360054 | 0.80 | CYP2D6 (0.54) | CYP2D6LMNAADRB2ADRB1ADRB3 | |
| SCHEMBL22359881 | 0.79 | CYP2D6 (0.52) | CYP2D6LMNAADRB2ADRB1ADRB3 | |
| SCHEMBL20964385 | 0.79 | CYP2D6 (0.49) | CYP2D6LMNAADRB2ADRB1ADRB3 | |
| SCHEMBL14922116 | 0.79 | CYP2D6 (0.59) | CYP2D6LMNAADRB2ADRB1ADRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210309633-A1 | INDAZOLE CARBOXAMIDES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-10-07 | — | — | US | disclosed |
| WO-2020235522-A1 | AMINOALKYL GROUP-CONTAINING ORGANOPOLYSILOXANE AND FIBER TREATMENT AGENT | 信越化学工業株式会社 (JP) | 2020-11-26 | — | — | WO | disclosed |
| US-20190127599-A1 | DISPERSION OF IR ABSORPTION PARTICLES, INKJET INK, AND METHOD OF 3D PRINTING | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2019-05-02 | — | — | US | disclosed |
| US-9079901-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2015-07-14 | — | — | US | disclosed |
| US-20150080370-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. | 2015-03-19 | — | — | US | disclosed |
| US-8703759-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| US-8202995-B2 | Pharmaceutically acceptable salts of aporphine derivatives and carboxyl group-containing agents and methods for preparing the same | STANDARD CHEM. & PHARM. CO., LTD. (TW) | 2012-06-19 | — | — | US | disclosed |
| US-20120010192-A1 | Fused Heterocyclic Compounds as Ion Channel Modulators | GILEAD SCIENCES, INC. | 2012-01-12 | — | — | US | disclosed |
| US-8093260-B2 | Aporphine derivatives and pharmaceutical use thereof | STANDARD CHEM. & PHARM. CO., LTD. (TW) | 2012-01-10 | — | — | US | disclosed |
| US-20090318488-A1 | Pharmaceutically acceprable salts of aporphine compounds of carboxyl group-containing agents and methods for preparing the same | STANDARD CHEM. & PHARM. CO., LTD. (TW) | 2009-12-24 | — | — | US | disclosed |
| US-20090318489-A1 | Aporphine compounds and pharmaceutical use thereof | STANDARD CHEM. & PHARM. CO., LTD. (TW) | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210309633-A1 | INDAZOLE CARBOXAMIDES AS KINASE INHIBITORS | RIPK3, RIPK1, RIPK2 | CYP2D6 2150/4885LMNA 3831/4885ADRB2 3761/4885 |
| US-20150080370-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNJ2, KCNH2, CACNA1E | CYP2D6 1520/4885LMNA 1181/4885ADRB2 257/4885 |
| US-20090318489-A1 | Aporphine compounds and pharmaceutical use thereof | IAPP, OPRL1, AGER | CYP2D6 551/4885LMNA 3468/4885ADRB2 70/4885 |
| US-20120010192-A1 | Fused Heterocyclic Compounds as Ion Channel Modulators | KCNJ2, KCNH2, CACNA1E | CYP2D6 1520/4885LMNA 1181/4885ADRB2 257/4885 |
| US-20090318488-A1 | Pharmaceutically acceprable salts of aporphine compounds of carboxyl group-containing agents and methods for preparing the same | IAPP, GPR119, AMY2A | CYP2D6 171/4885LMNA 3498/4885ADRB2 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.